Affy Warns of $20M Shortfall in Q3 Revenue
Affymetrix this week said that it expects a 21 percent drop in third-quarter revenues due to “increased competition for academic research funding and continued softness in industrial spending.”
The company said that total third-quarter 2008 revenue will be approximately $75 million. The company posted $95 million in revenue in the year-ago period and $84.7 million in the third quarter of 2006.
Kevin King, president of Affymetrix, said in a statement that the firm is "disappointed" with its results for the quarter and that it plans to complete an analysis of the shortfall to identify “specific actions that we intend to take to improve our operating results.”
Stephen Fodor, chairman and CEO of Affymetrix, said that the company expects that research budgets will remain “tight” in the near term, but added that the company believes that “the long term growth opportunity in the genetic analysis markets remains attractive.”
Fodor added that the company is “reengineering” its platform to offer products that are “more flexible and cost effective” in 2009.
Affymetrix will release its third-quarter financial results on Oct. 23.
VigeneTech, CapitalBio to Integrate Protein Array, Image Analysis Technologies
Imaging data analysis developer VigeneTech said this week that it has formed a partnership with Chinese biochip maker CapitalBio to develop protein array analysis solutions.
Under the agreement, the companies will integrate VigeneTech’s OEM software with CapitalBio’s LuxScan microarray scanners to market “fully integrated and personalized solutions,” CapitalBio said in a statement.
The first OEM products under the agreement will be developed around VigeneTech’s MicroVigene microarray image analysis software, and the hardware control component will be embedded in the MicroVigene protein array analysis suite. The firms believe it will “fulfill all of the demands of high quality and high throughput needed for array applications in all areas of clinical diagnostics and life science research.”
Financial terms of the alliance were not disclosed.
UK Service Provider Tepnel Adopts Illumina iScan Platform
Tepnel Life Sciences this week said that it has expanded its molecular genetic services offering to include Illumina's iScan System, the San Diego array maker’s next-generation scanner that provides researchers conducting genetic variation studies with greater throughput and application diversity.
Manchester-based Tepnel said it is now the first commercial provider of iScan services within the UK.
Tepnel offers a variety of platforms and techniques for SNP-based investigations for both human and non-human research and clinical applications in accordance with Good Laboratory Practice. David Scott, general manager of Tepnel's facility, said in a statement that the addition of iScan “opens up the possibility to our customers of whole genome association, focused content analysis, copy number variation analysis and, epigenetics on both human and non-human samples, all within a regulatory compliant environment."
Financial details of the purchase were not disclosed.
Gene Logic, deSciner to Create Interactive Genomics Resource
Gene Logic and deSciner Business Network announced last week that they will collaborate on the creation of an interactive genomics information resource, called Genomics Gateway.
The Genomics Gateway will be an interactive forum that includes input from genomic scientists, webinars, interviews, and blogs among other vehicles. It will be featured on new sections on deSciner’s OBBeC Biotech portal and Gene Logic’s "thought leadership forum."
Further details of the alliance were not provided.
Agilent Names Finland University as Service Provider
The Turku Centre for Biotechnology of the University of Turku and Abo Akademi University has been named a certified service provider for Agilent Technologies’ gene expression microarrays.
The center achieved the certified service provider status after completing training and passing “a rigorous series of assessments,” said Agilent.
“Our goal is to provide cutting-edge technology platforms to the research groups in life science both in Finland and internationally,” Riitta Lahesmaa, director of the center, said in a statement.
Seed Developer Enza Using Fluidigm for Quality Control
Integrated microfluidics systems maker Fluidigm said last week that vegetable seed developer Enza Zaden will use its technology under a deal through the distributor BIOKE.
Enza Zaden, which supplies seeds for agriculture, plans to use Fluidigm’s BioMark System for genetic engineering and the 96.96 Dynamic Array for seed supply quality control. The BioMark System uses integrated fluidic circuit technology for high-throughput genotyping, and the 96.96 can perform more than 9,200 simultaneous PCR experiments.
Netherlands-based Enza Zaden uses genetic markers to help choose seeds and to check hundreds of thousands of them for variety and flavor.